Contributions
Abstract: EP1786
Type: ePoster
Abstract Category: Therapy - disease modifying - 32 Others
Introduction: Previous prevalence studies suggest that patients with multiple sclerosis (MS) have higher frequency of sleep disorders comparing to healthy controls and that sleep disorders contribute in development of fatigue. However, the impact of disease-modifying therapy (DMT) on sleep of MS patients remains unknown.
Objectives: The aim of this study was to determine sleep characteristics in alemtuzumab treated MS patients and correlation between sleep disturbances and fatigue.
Methods: Out of 30 consecutive MS patients enrolled, 20 received alemtuzumab (12 females, mean age 40.00 +/- 8.96 years) and 10 (7 females, mean age 40.50 +/- 10.75 years) were treatment naïve. All subjects completed standardized Croatian version of Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), STOP-Bang Questionnaire, Restless Legs Syndrome Rating Scale (RLS-RS), Modified Fatigue Impact Scale (MFIS) and Fatigue Severity Scale (FSS).
Results: No statistically significant difference between treatment naïve and alemtuzumab treated patient group was observed in EDSS (median 1.50 vs 1.25, p=0.303). Treatment naïve patients had significantly higher RLS-RS score comparing to alemtuzumab treated patients (median 14.50 vs. 0, p=0.014). Also, positive correlation was found between ISI score and MFIS score (rs= 0.632, p=0.050) in treatment naïve group, whereas alemtuzumab treated patients had positive correlation between ISI score and MFIS score (rs= 0.629, p=0.004), ISI score and FFS score (rs= 0.650, p=0.003), PSQI score and MFIS score (rs= 0.664, p=0.003), PSQI score and FFS score (rs= 0.615, p=0.007).
Conclusion: Results of this study might suggest that alemtuzumab treatment eliminates other factors that contribute in development of fatigue besides sleep disorders. The remaining fatigue present in alemtuzumab treated patients might be more dependent on presence of sleep disorders than fatigue in treatment naïve patients.
Disclosure:
Barbara Barun participated as speaker and has received compensation for consulting services, travel expenses for scientific meetings from: Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche.
Magdalena Krbot Skorić: nothing to disclose.
Marina Mioč: nothing to disclose.
Luka Crnošija: nothing to disclose.
Ivan Adamec nothing to disclose.
Monika Mudrovčić: nothing to disclose.
Nataša Milošević: nothing to disclose.
Mario Habek participated as clinical investigator and/or speaker for: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals.
Abstract: EP1786
Type: ePoster
Abstract Category: Therapy - disease modifying - 32 Others
Introduction: Previous prevalence studies suggest that patients with multiple sclerosis (MS) have higher frequency of sleep disorders comparing to healthy controls and that sleep disorders contribute in development of fatigue. However, the impact of disease-modifying therapy (DMT) on sleep of MS patients remains unknown.
Objectives: The aim of this study was to determine sleep characteristics in alemtuzumab treated MS patients and correlation between sleep disturbances and fatigue.
Methods: Out of 30 consecutive MS patients enrolled, 20 received alemtuzumab (12 females, mean age 40.00 +/- 8.96 years) and 10 (7 females, mean age 40.50 +/- 10.75 years) were treatment naïve. All subjects completed standardized Croatian version of Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), STOP-Bang Questionnaire, Restless Legs Syndrome Rating Scale (RLS-RS), Modified Fatigue Impact Scale (MFIS) and Fatigue Severity Scale (FSS).
Results: No statistically significant difference between treatment naïve and alemtuzumab treated patient group was observed in EDSS (median 1.50 vs 1.25, p=0.303). Treatment naïve patients had significantly higher RLS-RS score comparing to alemtuzumab treated patients (median 14.50 vs. 0, p=0.014). Also, positive correlation was found between ISI score and MFIS score (rs= 0.632, p=0.050) in treatment naïve group, whereas alemtuzumab treated patients had positive correlation between ISI score and MFIS score (rs= 0.629, p=0.004), ISI score and FFS score (rs= 0.650, p=0.003), PSQI score and MFIS score (rs= 0.664, p=0.003), PSQI score and FFS score (rs= 0.615, p=0.007).
Conclusion: Results of this study might suggest that alemtuzumab treatment eliminates other factors that contribute in development of fatigue besides sleep disorders. The remaining fatigue present in alemtuzumab treated patients might be more dependent on presence of sleep disorders than fatigue in treatment naïve patients.
Disclosure:
Barbara Barun participated as speaker and has received compensation for consulting services, travel expenses for scientific meetings from: Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche.
Magdalena Krbot Skorić: nothing to disclose.
Marina Mioč: nothing to disclose.
Luka Crnošija: nothing to disclose.
Ivan Adamec nothing to disclose.
Monika Mudrovčić: nothing to disclose.
Nataša Milošević: nothing to disclose.
Mario Habek participated as clinical investigator and/or speaker for: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals.